Dr. Patel Discusses Checkpoint Blockade in NSCLC

Jyoti Patel, MD
Published: Wednesday, Oct 04, 2017



Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer (NSCLC).

There have been significant responses to checkpoint blockades, but only about 20% of patients demonstrate response.

The goal now is to bring the right immunotherapy agents to a broader population, says Patel, giving more patients a chance at response.
 


Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer (NSCLC).

There have been significant responses to checkpoint blockades, but only about 20% of patients demonstrate response.

The goal now is to bring the right immunotherapy agents to a broader population, says Patel, giving more patients a chance at response.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x